Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI

Study Background and Research Question

Spinal cord injury (SCI) remains a devastating clinical challenge, often resulting in permanent neurological deficits due to both primary mechanical trauma and a cascade of secondary damage. Secondary injury is largely driven by dysregulated neuroinflammation and cell death, including ferroptosis—a regulated cell death process characterized by iron-dependent lipid peroxidation. Erythropoietin (EPO), a glycoprotein hormone known for its hematopoietic function, has gained attention for its neuroprotective potential in SCI. However, systemic EPO delivery is hampered by poor accumulation at the lesion site and off-target effects, limiting its therapeutic translation. The core research question addressed by Lv et al. (Materials Today Bio, 2026) is whether a targeted, mRNA-based delivery system for EPO can overcome these barriers and effectively suppress ferroptosis and neuroinflammation at the site of SCI.

Key Innovation from the Reference Study

The study introduces a mannose-modified lipid nanoparticle (MLNP) platform engineered for targeted delivery of human erythropoietin mRNA (EPO mRNA) to CD206-positive inflammatory macrophages and microglia within injured spinal cord tissue. This design exploits surface mannose ligands to selectively direct the lipid nanoparticles to inflammation-associated cells, thus enabling localized and sustained EPO production. Critically, the approach leverages the capacity of mRNA therapeutics to induce on-site protein synthesis, circumventing the limitations of recombinant EPO protein delivery. The innovation lies in integrating cell-specific targeting, high encapsulation efficiency, and mRNA stability, resulting in improved lesion accumulation and functional protein translation after injury (reference study).

Methods and Experimental Design Insights

The research employed a rationally designed MLNP carrier system, functionalized with mannose residues to enhance uptake by CD206-enriched macrophages/microglia. Human EPO mRNA was encapsulated within these nanoparticles, and multiple in vitro and in vivo assays were conducted to validate their stability, targeting specificity, and biological activity. Key experimental components included:

• Nanoparticle Synthesis: Construction of MLNPs with well-defined physicochemical properties and surface mannose modification.
• Encapsulation and Characterization: Encapsulation efficiency, particle size, and mRNA stability were rigorously measured.
• Animal Model: A mouse model of spinal cord contusion injury was used to simulate clinically relevant SCI pathology.
• Targeting and Biodistribution: Fluorescent labeling and imaging confirmed preferential MLNP accumulation at the lesion site and selective uptake by CD206+ inflammatory cells.
• Outcome Measures: EPO protein expression in situ, neuroinflammatory markers, ferroptosis-associated gene expression, neuronal survival, axonal integrity, and motor function recovery were systematically assessed.
• Mechanistic Analysis: Transcriptomic profiling and biochemical assays were conducted to unravel the interplay between EPO treatment, iron metabolism, and lipid peroxidation pathways.

Protocol Parameters

• MLNP formulation: Mannose-modified lipids at optimized molar ratios for selective CD206 targeting.
• mRNA encapsulation: High-purity in vitro transcribed human EPO mRNA with poly(A) tail and cap structure for enhanced translation.
• Dosage and administration: Systemic injection post-SCI; timing and dose calibrated to maximize lesion accumulation and minimize systemic exposure.
• Outcome timing: Neuroinflammation, ferroptosis markers, and motor function evaluated at acute and subacute timepoints post-injury.

Core Findings and Why They Matter

The MLNP-mediated delivery of EPO mRNA led to several significant outcomes:

• Efficient Targeting and Sustained Expression: EPO@MLNPs efficiently accumulated at the SCI lesion and enabled sustained local synthesis of EPO protein, overcoming the delivery limitations of exogenous EPO (reference).
• Suppression of Neuroinflammation: The treatment markedly reduced expression of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), indicating effective modulation of the inflammatory microenvironment.
• Inhibition of Ferroptosis: Integrated transcriptomic and biochemical analyses revealed downregulation of ferroptosis-related pathways, including normalization of iron metabolism and lipid peroxidation, and upregulation of anti-ferroptotic regulator GPX4.
• Neuroprotection and Functional Recovery: EPO@MLNP-treated mice exhibited reduced neuronal loss, preserved serotonergic axons, and significantly improved motor function compared to controls.

These results establish that inflammation-targeted, mRNA-based EPO delivery can address both primary drivers of secondary SCI damage—neuroinflammation and ferroptosis—offering a dual-action therapeutic strategy with clear translational potential.

Comparison with Existing Internal Articles

Several internal reviews and analyses have contextualized advances in mRNA-based neurorepair, particularly through the lens of EPO mRNA delivery. For example, Targeted EPO mRNA Nanoparticles Suppress Ferroptosis in SCI synthesizes how mannose-modified nanoparticles facilitate site-specific EPO expression and ferroptosis suppression, closely paralleling the design and outcomes of the present study. Similarly, EZ Cap™ EPO mRNA: Redefining Translational Neurorepair provides a mechanistic discussion of how mRNA stability, capping, and targeted delivery are critical to achieving robust protein expression and functional benefit in neurorepair models. These internal resources highlight the strategic importance of advanced mRNA for erythropoiesis research and neuroprotection, underscoring the translational bridge from in vitro design to in vivo efficacy.

Limitations and Transferability

While the targeted MLNP-EPO mRNA system demonstrates robust efficacy in mouse models, several limitations must be acknowledged. The immunological and biodistribution profiles in humans may differ, and potential off-target effects of mannose-modified carriers need further assessment. Additionally, the long-term effects of sustained EPO expression in the CNS are not fully understood. Transferability to other neuroinflammatory or neurodegenerative conditions will require direct evaluation, as the SCI context presents unique challenges in barrier penetration and inflammatory cell targeting. Nonetheless, the study provides a valuable preclinical framework for developing mRNA for gene therapy and protein expression studies in neurorepair.

Research Support Resources

Researchers aiming to replicate or extend these findings may require high-quality, translation-ready mRNA for erythropoiesis or neurorepair studies. Products such as EZ Cap™ EPO mRNA (ψUTP) (SKU R1020) from APExBIO offer in vitro transcribed human erythropoietin mRNA with a Cap 1 structure and pseudouridine modifications, which are known to enhance mRNA stability and translation efficiency while minimizing immune activation. These features align with the requirements for advanced mRNA delivery workflows, as highlighted in both the referenced study and internal reviews. Proper handling and storage at or below -40°C are strongly recommended to maintain mRNA integrity during experimental workflows.